<DOC>
	<DOCNO>NCT00581308</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy GORE® HELEX® Septal Occluder treatment ostium secundum atrial septal defect ( ASDs ) .</brief_summary>
	<brief_title>Long-term Safety Study GORE® HELEX® Septal Occluder</brief_title>
	<detailed_description>The GORE® HELEX® Septal Occluder approve medical device indicate transcatheter closure atrial septal defect ( ASDs ) . The purpose study evaluate long-term safety efficacy GORE® HELEX® Septal Occluder treatment ostium secundum atrial septal defect ( ASDs ) . This FDA Condition Approval Study . All subject enrol study follow long-term safety efficacy occluder device 5 year .</detailed_description>
	<mesh_term>Heart Septal Defects</mesh_term>
	<mesh_term>Heart Septal Defects , Atrial</mesh_term>
	<criteria>ASD le equal 18 mm . Conditions would confound treatment ASD complicate distinguish onset adverse event . Unable accommodate device delivery catheter .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>atrial septal defect , septal occluder , HELEX</keyword>
</DOC>